FLNA
FILANA THERAPEUTICS, INC.Company Information
- Company Name
- FILANA THERAPEUTICS, INC.
- CIK
- CIK0001069530
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- FLNA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- FLNA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-28
- Last sale
- 2024-11-29
- Shares purchased (TTM)
- 338,801
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 12,046,227
- Shares outstanding
- 48,307,896
- Ownership
- 24.94%
Earnings Market Reaction
- Filing date
- 2026-05-07
- Price on filing date
- —
- 1-month reaction
- 13.24%
- 3-month reaction
- -34.56%
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 87 | 96 | 106 | 112 | 117 | 129 | 149 | 207 | 124 | 121 | 142 | 168 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | 40 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 2 | 3 | 2 | 3 | 8 | 14 | 15 | 10 | 8 | 8 | 8 | ||||||
| Assets Current | 88 | 98 | 109 | 115 | 120 | 137 | 203 | 222 | 134 | 130 | 150 | 175 | ||||||
| Property Plant And Equipment Net | 20 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 22 | 22 | 22 | 22 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | 0 | 0 | - | ||||||
| Assets | 108 | 118 | 130 | 135 | 141 | 158 | 224 | 244 | 156 | 152 | 173 | 197 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | 39 | 42 | 46 | 43 | 8 | 8 | 52 | 53 | 10 | 11 | 9 | 10 | ||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 7 | ||||||
| Employee Related Liabilities Current | 0 | 2 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | - | - | 65 | - | - | - | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 40 | 44 | 48 | 47 | 13 | 12 | 57 | 55 | 77 | 14 | 17 | 18 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | 0 | 0 | - | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | - | ||||||
| Liabilities | 40 | 44 | 48 | 47 | 13 | 12 | 57 | - | - | 14 | 17 | 18 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 575 | 570 | 565 | 561 | 556 | 551 | 544 | 538 | 434 | 518 | 515 | 514 | ||||||
| Retained Earnings Accumulated Deficit | -506 | -496 | -484 | -473 | -429 | -405 | -378 | -350 | -356 | -381 | -360 | -334 | ||||||
| Stockholders Equity | 68 | 74 | 82 | 88 | 128 | 146 | 167 | 189 | 79 | 137 | 155 | 179 | ||||||
| Liabilities And Stockholders Equity | 108 | 118 | 130 | 135 | 141 | 158 | 224 | 244 | 156 | 152 | 173 | 197 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | ||||||
| Common Stock Shares Issued | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 43 | 42 | 42 | 42 | ||||||
| Shares Outstanding | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 43 | 42 | 42 | 42 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFILANA THERAPEUTICS, INC. (FLNA) — SEC Financial Statements & Analysis
FILANA THERAPEUTICS, INC. (FLNA) is a pharmaceutical preparations company, incorporated in DE. FILANA THERAPEUTICS, INC. trades on Nasdaq as: FLNA. FILANA THERAPEUTICS, INC. (FLNA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-07. Based on that filing, FILANA THERAPEUTICS, INC. carries a market cap of $81.64M, a P/E ratio of -1.05x, a P/B ratio of 1.20x, an enterprise value of $-4.93M, and an EV/EBITDA multiple of 0.06x. On profitability, it posts a Return on Equity (ROE) of -79.59%, a Return on Assets (ROA) of -62.50%, and a Return on Invested Capital (ROIC) of -845.41%. Per share, it reports EPS of $-1.61, diluted EPS of $-1.88, free cash flow per share of $-0.63, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 7.02% year-over-year and EPS growth of 6.92% year-over-year. On the balance sheet, it maintains a current ratio of 2.19x, a quick ratio of 2.16x, working capital of $47.85M, a debt-to-equity ratio of 0.59x, a debt ratio of 0.37, an interest coverage ratio of -19.78x, free cash flow of $-30.38M (TTM), and net debt of $-86.57M. Figures sourced from SEC EDGAR.
- Market Cap
- $81.64M
- P/E TTM
- -1.05x
- EPS TTM
- $-1.61
- P/B TTM
- 1.20x
- ROE TTM
- -79.59%
- ROA TTM
- -62.50%
- Debt To Equity
- 0.59x
- Free Cash Flow TTM
- $-30.38M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is FILANA THERAPEUTICS, INC. in?
FILANA THERAPEUTICS, INC. (FLNA) operates in the Pharmaceutical Preparations industry.
What exchange does FLNA trade on?
FILANA THERAPEUTICS, INC. (FLNA) trades on the Nasdaq.
Where is FILANA THERAPEUTICS, INC. incorporated?
FILANA THERAPEUTICS, INC. is incorporated in DE.
When was FILANA THERAPEUTICS, INC. (FLNA)'s most recent SEC filing?
FILANA THERAPEUTICS, INC. (FLNA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-07.
What is FLNA's market cap?
FILANA THERAPEUTICS, INC. (FLNA) has a market capitalization of $81.64M as of 2026-03-31.
What is FLNA's EPS (earnings per share)?
FILANA THERAPEUTICS, INC. (FLNA)'s trailing twelve month EPS is $-1.61 as of 2026-03-31.
What is FLNA's ROE (return on equity)?
FILANA THERAPEUTICS, INC. (FLNA)'s trailing twelve month Return on Equity (ROE) is -79.59% as of 2026-03-31.
What is FLNA's ROA (return on assets)?
FILANA THERAPEUTICS, INC. (FLNA)'s trailing twelve month Return on Assets (ROA) is -62.50% as of 2026-03-31.
What is FLNA's ROIC (return on invested capital)?
FILANA THERAPEUTICS, INC. (FLNA)'s trailing twelve month Return on Invested Capital (ROIC) is -845.41% as of 2024-12-31.
What is FLNA's EV/EBITDA?
FILANA THERAPEUTICS, INC. (FLNA)'s trailing twelve month EV/EBITDA is 0.06x as of 2026-03-31.